---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-007369"
form_type: "8-K"
ticker: "BTCY"
cik: "0001630113"
company_name: "BIOTRICITY INC."
filed_at: "2026-02-18T23:59:59+00:00"
generated_at: "2026-05-16T02:05:11.288969+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biotricity Q3 FY26 revenue up 10% to $4M; net loss narrows 13% to $1.1M

## Summary
- Revenue $4M (+10.2% YoY); gross margin expanded to 81.5% from 76.4%.
- Net loss $1.1M ($0.042 per share) vs $1.3M ($0.054 per share) prior year.
- Third consecutive quarter of positive EBITDA and net operating income.
- Recurring TaaS revenue $3.6M (91.2% of total); customer retention 90%+.
- FDA clearance for AI clinical model expected in coming months.

## SEC filing metadata
- accession: 0001493152-26-007369
- form_type: 8-K
- ticker: BTCY
- cik: 0001630113
- company_name: BIOTRICITY INC.
- filed_at: 2026-02-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630113/000149315226007369/0001493152-26-007369-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630113/000149315226007369/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-007369
- JSON: https://secwatch.observer/filing/0001493152-26-007369.json
- Plain text: https://secwatch.observer/filing/0001493152-26-007369.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.